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The speciﬁc phosphorylation of inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) in the 3-
position (EC 2.7.1.127) was discovered 20 yr ago (Batty et al., 1985; Irvine et al., 1986a, b).
At that time it represented an unexpected complication in the metabolism of Ins(1,4,5)P3,
whose second messenger function was just emerging (Streb et al., 1983; Berridge and
Irvine, 1984). Moreover, given that we already knew that Ins(1,4,5)P3 can be inactivated
by a speciﬁc 5-phosphatase (EC 3.1.3.56) (Downes et al., 1982), it was something of a
puzzle as to why cells should also consume ATP to phosphorylate Ins(1,4,5)P3. This
conundrum was further enhanced when we found that Ins(1,3,4,5)P4 did not mobilize
Ca2+ (Irvine et al., 1986a, b) so, superﬁcially, Ins(1,4,5)P3 3-kinase (IP33K) could indeed
be viewed as just a ‘redundant’ off-switch for Ins(1,4,5)P3.
In the ensuing time, we have learned an enormous amount about the three members of
the mammalian IP33K family (for reviews of their overall molecular biology and properties
see Communi et al. (1995); Irvine and Schell (2001); Pattni and Banting (2004)). We have
also gone a long way towards an understanding of the ‘why’ question—why do cells bother
to make Ins(1,3,4,5)P4, and consume an ATP molecule, when they have a perfectly good 5-
phosphatase to inactivate Ins(1,4,5)P3? The answer to this question is a long and
complicated one, and its principal components lie ﬁrstly in our knowledge of the evolution
of the IP33Ks and, secondly, in what we know about their localization and regulation.2006 Elsevier Ltd.
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One of our major sources of enlightenment has stemmed from an understanding of
where IP33Ks came from. We now know that IP33K is a member of a larger family of
enzymes that began early in eukaryotic evolution (Irvine and Schell, 2001; Irvine, 2005),
either as ‘InsP3 multi-kinases’ (EC 2.7.1.151, i.e., inositol phosphate kinases that can
phosphorylate several substrates), or InsP6 kinases (EC 2.7.4.21). Together these enzymes
form a major part of a route of synthesis of the pyro-phosphorylated inositol phosphates
Ins(PP)P5 and Ins(PP)2P4 (more loosely known as InsP7 and InsP8, respectively).
Discussion of these pathways and their functions can be found in, e.g., Irvine and Schell
(2001); Shears (2001); Irvine (2005); York et al. (2005), and we return to them at the end of
this review. Note that a particularly intriguing possible function for Ins(PP)P5 has
emerged recently with the suggestion that it may directly (and non-enzymatically)
phosphorylate some proteins, particularly proteins found in the nucleolus (Saiardi et al.,
2004).
From this recent cloning activity we can see that the IP33Ks evolved out of an inositol
phosphate kinase family late in eukaryotic evolution, probably about the time when
metazoans emerged (Irvine and Schell, 2001). Moreover, from a comparison of the
primary sequences of the family viewed in the context of how IP33KA binds its
Ins(1,4,5)P3 substrate with such exquisite speciﬁcity (Gonzalez et al., 2004), we can see that
the crucial evolutionary change was the insertion of three extra a-helices in the InsP-
binding domain. This insertion holds the Ins(1,4,5)P3-binding residues in a precise
orientation (see Fig. 1), and ensures an absolute speciﬁcity for the substrate, including not
least ensuring that it will not phosphorylate PtdIns(4,5)P2 to generate the (already
established when IP33Ks evolved) second messenger PtdIns(3,4,5)P3 (Gonzalez et al., 2004;
Miller and Hurley, 2004); note the contrast (Fig. 1) with the related ‘InsP3 multikinase’,
which lacks these three a-helices (Gonzalez et al., 2004), and can phosphorylate
PtdIns(4,5)P2 to PtdIns(3,4,5)P3 (Resnick et al., 2005). So, as the ﬁrst IP33K emerged in
the form of a speciﬁc Ins(1,4,5)P3 3-kinase, why did evolution seize on it, keep it and use it
extensively? The answer to this lies in the three possible functions of IP33Ks, and it is theseFig. 1. Ins(1,4,5)P3 binding to IP3KA. This illustration is derived from the structure of IP3KA with Ins(1,4,5)P3
and ATP bound to it, as described by Gonzalez et al. (2004). On the left is the original structure, and on the right
is exactly the same, but with the three-helices insert (IP lobe) that is unique to the Ins(1,4,5)P3 3-kinases (Gonzalez
et al., 2004) removed. Thus, the structure on the right envisions how Ins(1,4,5)P3 might bind to an InsP3
multikinase (lacking these three helices) which could, therefore, enable a wider range of substrates binding,
including PtdIns(4,5)P2 (Resnick et al., 2005).
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the rest of this paper.
In simple terms, there are three possible functions for IP33Ks: (a) to remove
Ins(1,4,5)P3, thus terminating its second messenger function; (b) to synthesize
Ins(1,3,4,5)P4, which acts as a second messenger in its own right; and (c) to serve as the
ﬁrst step in a route of synthesis of the higher inositol phosphates.
Functions (a)—removal of Ins(1,4,5)P3
As hinted at above, to avoid redundancy of IP33K with Ins(1,4,5)P3 5-phosphatase as a
remover of Ins(1,4,5)P3, we would expect there to be clear differences between the two
enzymes in terms of their physiology. Indirect evidence for this comes from the different
phenotypes engendered in Caenorhabditis elegans when the IP33K (Clandinin et al., 1998)
versus the Ins(1,4,5)P3 5-phosphatase (Bui and Sternberg, 2002) are knocked out. The ﬁrst
difference in actual properties between the two enzymes to be discovered was that IP33K
has a higher afﬁnity but lower Vmax than Ins(1,4,5)P3 5-phosphatase (Irvine et al., 1986a, b;
Connolly et al., 1987), implying that perhaps IP33K is the principal route of Ins(1,4,5)P3
metabolism in cells, with the phosphatase being there to remove rapidly any excess
Ins(1,4,5)P3 (a relationship reminiscent of that between the high-afﬁnity, low-capacity
Ca2+-ATPases, and the low-afﬁnity, high-capacity Ca2+/Na+ exchangers). One might,
therefore, expect that at low doses of agonists (and thus at low Ins(1,4,5)P3 levels) the
route of Ins(1,4,5)P3 metabolism is mostly by the kinase, and some data on inositol
phosphates generated support that suggestion indirectly. But interestingly, in mice with
either IP33KA (Jun et al., 1998) or IP33KB (Pouillon et al., 2003) knocked out, the authors
reported no difference in Ins(1,4,5)P3 levels in relevant tissues, whereas in cells with
reduced Ins(1,4,5)P3 5-phosphatase, the authors documented increased Ins(1,4,5)P3 levels,
leading to a change in cellular physiology (Speed et al., 1999). These issues may
be complicated by the possible existence of multiple pools of Ins(1,4,5)P3 (see (Irvine
and Schell, 2001 for discussion) and, overall, we still have no clear answer to the
relative contributions of the two enzymes to Ins(1,4,5)P3 removal; it may be that it
varies between tissues and organisms. More interesting and compelling evidence for a
separation of the functions of the two enzymes lies in their very different regulation and
localization.
At an early stage in its evolution, some time between the emergence of nematodes and
arthropods (Irvine and Schell, 2001), IP33K became regulated by Ca
2+/calmodulin
(Communi et al., 1995). Later (in vertebrates), some IP33K isoforms became activatable by
phosphorylation on a threonine residue that is close to the catalytic site (Gonzalez et al.,
2004) by CaMKII (Communi et al., 1997, 1999). This is in marked contrast to the
inhibition of Ins(1,4,5)P3 5-phosphatase caused by CaMKII phosphorylation (Communi
et al., 2001). Thus, an activation of CaMKII will divert Ins(1,4,5)P3 speciﬁcally towards
Ins(1,3,4,5)P4, which might be taken as indirect evidence for some speciﬁc function of the
latter (see below).
Another factor that separates the kinase and phosphatase is their distinctly different
localization. The Ins(1,4,5)P3 5-phosphatase is localized to the plasma membrane by being
farnesylated (De Smedt et al., 1997). However, the A and B isoforms of IP33K are targeted
either to the actin skeleton or to the endoplasmic reticulum (e.r.), and this targeting and its
regulation represents a crucial aspect of their physiological function.
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The localization of the C isoform of IP33K is controversial in that one group have
claimed a partially nuclear (and dynamic) localization (Nalaskowski et al., 2003), and the
other a cytosolic localization (Dewaste et al., 2003). We will not discuss this issue further,
but will instead focus on the localization of the A and B isoforms, which is more fully
understood.
IP33KA is conﬁned to the testis and to neurons, and in neurons its localization is
dynamic and under tight regulation. IP33KA is expressed at highest levels in the cerebellum
and the hippocampus, especially in the neuropil of the CA1 and dentate gyrus regions of
the latter (Mailleux et al., 1991; Schell and Irvine, 2006). Moreover, this high level of
enzyme is further concentrated by a clear localization to the post-dendritic spines of the
neurons, a localization that is effected by a speciﬁc and novel F-actin binding domain
consisting of the N-terminal 66 amino acids of IP33KA (Schell et al., 2001). In such a
position, where it lies between the major site of Ins(1,4,5)P3 generation (by the post-
synaptic density) and the site of its action (the e.r.), IP33KA is perfectly poised to act as a
sort of ‘ﬁrewall’ (Schell et al., 2001), dictating by its activity the degree to which
Ins(1,4,5)P3 can ‘escape’ from the spine and mobilize Ca
2+ (Schell et al., 2001). The acute
and long-term regulation of IP33KA by Ca
2+ that is discussed above can then be viewed as
a way in which stimulation of a spine to increase its Ca2+ will in turn dictate how it
regulates the actions of Ins(1,4,5)P3.
We have explored this activation by Ca2+ in transfected cells (SML-B, JCHY, RFI and
MJS, unpublished), and shown that even in a simple system like a HeLa cell, the inﬂuence
of calmodulin and CaMKII is detectable in the ability of IP33KA to decrease Ins(1,4,5)P3-
induced Ca2+ mobilization. Moreover, the localization to the actin skeleton also has a
clear effect on the efﬁcacy of IP33KA, again, even in such an unpolarized cell as a HeLa
(SML-B, JCHY, RFI and MJS, unpublished), so when we consider such a highly polarized
structure as a dendrite, the localization of IP33KA adds a new dimension to the inter-
relationship between the various stimulatory inputs into postsynaptic spines (Schell et al.,
2001).
Our more recent investigations of IP33KA have now added another crucial dimension to
this complexity, the dimension of time. Firstly, by using IP33KA as a sort of real-time
marker for F-actin, we have revealed that the F-actin in spines is in a highly dynamic state.
As far as we can tell it is not turning over very rapidly, but rather the entire F-actin is in a
state of dynamic equilibrium, whereby Ca2+ entry (especially through NMDA receptors)
is driving it as a single entity out of the spines and into the main dendritic shaft (Fig. 2 and
(Schell and Irvine, 2006)), carrying IP33KA with it. This is a physiological response in so
far as resting synaptic activity has a signiﬁcant effect on IP33KA localization (Schell and
Irvine, 2006). Moreover, at high levels of stimulation with exogenous glutamate, which
could be taken as a mimicking of massive stimulation such as follows ischemic shock, the
exit of IP33KA is total and rapid (within seconds), and may form the ﬁrst stage in the
pronounced changes in spine structure that follow such events (Halpain et al., 1998). It is
important to note, however, that provided the stimulation with glutamate is not too
prolonged, it remains fully reversible within about 20min (Fig. 2 and (Schell and Irvine,
2006)). It remains to be seen what the functional consequences of this movement of
IP33KA are—as we have discussed elsewhere (Schell and Irvine, 2006); both removing
IP33KA from the spines and placing it in the shafts will have profound consequences for
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Fig. 2. Dynamic localization of Ins(1,4,5)P3 3-kinase A in postsynaptic spines. The ﬁgure shows IP3KA
transfected into hippocampal neurones, and illustrates (A) before, (B) 2min after, treatment with 100 mM
glutamate, and (C) 20min after removal of 100mM glutamate and the addition of MK-801, an NMDA receptor
antagonist. The reversible shift from the spines to the shaft induced by glutamate is plainly visible. See (Schell and
Irvine, 2006) for all details.
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2+ signalling. Moreover, as the principal Ins(1,4,5)P3-generating
receptors in this system (metabotropic and muscarinic) have a minimal inﬂuence on
IP33KA movement, another consequence of these discoveries is to expand the complexity
of the relationship between the different types of glutamate receptors.
Secondly, an extra layer of complexity in the dimension of time can be found in the
spatial relationship between the e.r. and the actin skeleton. Our three-dimensional
reconstruction of images (Schell and Irvine, 2006) has conﬁrmed the close spatial
relationship between these structures in those spines into which the e.r. penetrates (Capani
et al., 2001). However, all these images depict motionless structures, and the picture
changes when we think about how spines themselves are moving (Fischer et al., 1998), and
that movement itself impinges on the Ca2+ kinetics within the spine (Majewska et al.,
2000). Moreover, we have shown that the e.r. itself is a highly motile organelle whose
movements are under acute regulation by Ca2+ in both ATP-dependent and independent
mechanisms (Brough et al., 2005a, b). Taking this remarkable complexity concerning
IP33KA and the actions of Ins(1,4,5)P3 in dendrites overall, we can begin to see that there
is no functional redundancy with Ins(1,4,5)P3 5-phosphatase—in parallel experiments to
those described above (Schell and Irvine, 2006), Ins(1,4,5)P3 5-phosphatase does not
localize to dendritic spines, but is instead distributed all along the plasma membrane of the
dendrite, and it does not move perceptibly when glutamate is added (MJS and RFI,
unpublished). Thus, it makes every sense that a primary function of IP33KA could be to
remove Ins(1,4,5)P3.
Finally, a brief consideration of IP33KB supports this conclusion. Our understanding of
the regulation of this isoform is not quite so advanced as for IP33KA but, nevertheless, we
know that in addition to its dual stimulation by CaM and CaMKII (Communi et al.,
1999), IP33KB also has an interesting localization as a part of its function. Originally, it
was described as being either cytosolic or in the e.r. (Soriano et al., 1997), but subsequent
cloning of the full length enzyme (the original cloning was missing some of the N-terminus)
has led to the realization that it is partially localized to the cytoskeleton (Dewaste et al.,
2003), because it too has an actin-binding domain (Brehm et al., 2004). The localization in
the e.r. is due to a distinct part of the N-terminus (Pattni et al., 2003), and we have recently
shown that removal of the ﬁrst 150 amino acids from the N-terminus of IP33KB causes the
enzyme to move from the actin skeleton to the e.r. (Yu et al., 2005). Moreover, this
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2005), an event that we have shown takes place under physiological conditions, at least
with the transfected enzyme (Yu et al., 2005). Finally, as with the A-isoform (SML-B,
JCHY, RFI and MJS, unpublished), the localization of the enzyme alters its ability
to metabolize Ins(1,4,5)P3, as assayed by decreases in Ins(1,4,5)P3-induced Ca
2+ signals
(Yu et al., 2005).
Functions (b)—synthesis of Ins (1,3,4,5)P4
The possibility that Ins(1,3,4,5)P4 is a second messenger in its own right has been
extensively discussed elsewhere (e.g. Irvine and Schell, 2001), and needs no expansion here.
The only directly relevant recent information concerns our own attempts to gain evidence
for the hypothesis (Irvine, 1989; Soriano and Banting, 1997; Irvine and Schell, 2001) that
Ins(1,3,4,5)P4 acts to modify the structure of the e.r., thus regulating the mobilization of
Ca2+ from the e.r. by Ins(1,4,5)P3. We have made concerted effort to seek evidence for
such an effect on e.r. structure or movement using FRAP in several cell preparations, but
have had to conclude either that the hypothesis is wrong, or that it cannot be detected by
the technology we used (Brough et al., 2005a, b). There remain intriguing and strong data
showing that Ins(1,3,4,5)P4 can exert profound inﬂuences on Ins(1,4,5)P3-regulated Ca
2+
homeostasis (e.g. (Changya et al., 1989; Loomis-Husselbee et al., 1996), but the mechanism
or universality of such responses remain unclear.
A very enticing indirect piece of evidence emerged recently from two independent
reports that in the absence of the activity of IP33KB, mice cannot mature their T cells,
leading to immunocompromized animals (Pouillon et al., 2003; Wen et al., 2004).
T lymphocyte Ca2+ signalling appeared superﬁcially normal in both studies, and Wen
et al. (2004) presented evidence that MAP kinase signalling might be altered. Both groups
raised the issue that GAP1IP4BP, a putative Ins(1,3,4,5)P4 receptor (Cullen et al., 1995,
1997), which is very highly expressed in circulating lymphocytes (Lockyer et al., 1999),
might be the protein involved, thus directly implicating Ins(1,3,4,5)P4 as the important
factor missing in these mice.
Subject to some caveats, these ﬁndings are arguably the most compelling evidence yet
that Ins(1,3,4,5)P4 is a physiological second messenger. The two caveats to this
interpretation are, ﬁrstly that, as has been shown for many other proteins (including,
e.g., the yeast InsP3 multikinase (Dubois et al., 2000) and PI-PLCg (Patterson et al.,
2002)), IP33KB may play a structural role, independent of its catlytic activity, as an
indispensible member of a multi-protein complex. The second caveat is that the important
missing component may be InsP6 (or another higher inositol phosphate), rather than
Ins(1,3,4,5)P4.
Functions (c)—the first step in the synthesis of higher inositol phosphates
The suggested synthesis pathway in mammalian cells for the higher inositol phosphates
(functionally the most interesting of these are currently: Ins(3,4,5,6)P4, Ins(1,3,4,5,6)P5,
InsP6, InsP7 and InsP8 (see Irvine and Schell (2001); Shears (2001); Irvine (2005) for
reviews)) was ﬁrst pieced together largely by Shears and Balla and their co-workers in the
1980s (Balla et al., 1989; Shears, 1989). The cloning of inositol phosphate kinases in the
following decades culminated in the identiﬁcation of all the enzymes responsible for this
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Fig. 3. Pathways of InsP6 synthesis. The ﬁgure depicts the two likely pathways for InsP6 synthesis in mammlian
cells. One route, the upper pathway (Odom et al., 2000), is found in yeast, may exist in mammals and does not
involve any Ins(1,4,5)P3 3-kinase activity. The lower route (Balla et al., 1989; Shears, 1989) has IP33K as an
essential ﬁrst step.
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Ins(1,3,4,6)P4 to Ins(1,3,4,5,6)P5 to InsP6 to InsP7 (InsP7 kinase has yet to be cloned).
If this is indeed the major pathway by which animals make InsP6, then acting as the ﬁrst
step on it is another potentially very important function for IP33Ks. Elsewhere, the
arguments for and against whether other pathways of InsP6 synthesis are equally or more
important are discussed (Irvine, 2005), and these would not be repeated here. In this
context, the crucial issue is whether the ‘missing factor’ in IP33KB knock-out mice
(Pouillon et al., 2003; Wen et al., 2004) is Ins(1,3,4,5)P4 itself, or another component of the
above pathway. As mice lacking ‘InsP3 multikinase’ (Frederick et al., 2005) or InsP5
2-kinase (Verbsky et al., 2005) die at birth (compare the less severe phenotypes of IP33K
knock-out mice, above), superﬁcially, it seems likely that IP33K is not essential to higher
inositol phosphate synthesis. We have recently set up a highly speciﬁc and sensitive mass
assay for InsP6 (RF I, AJL and MJS, unpublished), and by assessing the levels of InsP6 in
the above knock-out mice with this assay we hope to shed light on this issue.
Summary
It is 20 yr since the Ins(1,4,5)P3 3-kinase reaction was discovered, and this review
summarizes and discusses some of the advances we have made in our understanding of the
physiological signiﬁcance of this reaction. The three major potential functions of
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possible functions of their product, Ins(1,3,4,5)P4 and their potential contribution to the
synthesis of higher inositol polyphosphates.Acknowledgements
Our work is supported by the Royal Society (RFI, MJS), the Wellcome Trust (RFI,
AJL), the Croucher Foundation (JCHY) and Merck Sharp and Doehme (SML-B).References
Balla T, Baukal AJ, Hunyady L, Catt KJ. Agonist-induced regulation of inositol tetrakisphosphate isomers and
inositol pentakisphosphate in adrenal glomerulosa cells. J Biol Chem 1989;264:13605–11.
Batty IR, Nahorski SR, Irvine RF. Rapid formation of inositol 1,3,4,5-tetrakisphosphate following muscarinic
receptor stimulation of rat cortical slices. Biochem J 1985;232:211–5.
Berridge MJ, Irvine RF. Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature
1984;312:315–21.
Brehm MA, Schreiber I, Bertsch U, Wegner A, Mayr GW. Identiﬁcation of the actin-binding domain of
Ins(1,4,5)P3 3-kinase isoform B (IP3K-B). Biochem J 2004;382:353–62.
Brough D, Sim Y, Thorn P, Irvine RF. The structural integrity of the endoplasmic reticulum, and its possible
regulation by inositol 1,3,4,5-tetrakisphosphate. Cell Calcium 2005a;38:153–9.
Brough D, Schell MJ, Irvine RF. Agonist-induced regulation of mitochondrial and endoplasmic reticulum
motility. Biochem J 2005b;392:291–7.
Bui YK, Sternberg PW. Caenorhabditis elegans inositol 5-phosphatase homolog negatively regulates inositol 1,4,5-
triphosphate signaling in ovulation. Mol Biol Cell 2002;13:1641–51.
Capani F, Martone ME, Deerinck TJ, Ellisman MH. Selective localization of high concentrations of F-actin in
subpopulations of dendritic spines in rat central nervous system: a three-dimensional electron microscopic
study. J Comput Neurol 2001;435:156–70.
Changya L, Gallacher DV, Irvine RF, Potter BV, Petersen OH. Inositol 1,3,4,5-tetrakisphosphate is essential for
sustained activation of the Ca2+-dependent K+ current in single internally perfused mouse lacrimal acinar
cells. J Membr Biol 1989;109:85–93.
Clandinin TR, DeModena JA, Sternberg PW. Inositol trisphosphate mediates a RAS-independent response to
LET-23 receptor tyrosine kinase activation in C. elegans. Cell 1998;92:523–33.
Communi D, Vanweyenberg V, Erneux C. Molecular study and regulation of D-myo-inositol 1,4,5-trisphosphate
3-kinase. Cell Signal 1995;7:643–50.
Communi D, Vanweyenberg V, Erneux C. D-myo-inositol 1,4,5-trisphosphate 3-kinase A is activated by receptor
activation through a calcium:calmodulin-dependent protein kinase II phosphorylation mechanism. EMBO
J 1997;16:1943–52.
Communi D, Dewaste V, Erneux C. Calcium–calmodulin-dependent protein kinase II and protein kinase
C-mediated phosphorylation and activation of D-myo-inositol 1,4, 5-trisphosphate 3-kinase B in astrocytes.
J Biol Chem 1999;274:14734–42.
Communi D, Gevaert K, Demol H, Vandekerckhove J, Erneux C. A novel receptor-mediated regulation
mechanism of type I inositol polyphosphate 5-phosphatase by calcium/calmodulin-dependent protein kinase II
phosphorylation. J Biol Chem 2001;276:38738–47.
Connolly TM, Bansal VS, Bross TE, Irvine RF, Majerus PW. The metabolism of tris- and tetraphosphates of
inositol by 5-phosphomonoesterase and 3-kinase enzymes. J Biol Chem 1987;262:2146–9.
Cullen PJ, Hsuan JJ, Truong O, Letcher AJ, Jackson TR, Dawson AP, et al. Identiﬁcation of a speciﬁc
Ins(1,3,4,5)P4-binding protein as a member of the GAP1 family. Nature 1995;376:527–30.
Cullen PJ, Loomis-Husselbee JW, Dawson AP, Irvine RF. Inositol 1,3,4,5-tetrakisphosphate and Ca2+
homeostasis—the role of GAP1IP4BP. Biochem Soc Trans 1997;25:991–6.
De Smedt F, Missiaen L, Parys JB, Vanweyenberg V, De Smedt H, Erneux C. Isoprenylated human brain type I
inositol 1,4,5-trisphosphate 5-phosphatase controls Ca2+ oscillations induced by ATP in Chinese hamster
ovary cells. J Biol Chem 1997;272:17367–75.
ARTICLE IN PRESS
R.F. Irvine et al. / Advan. Enzyme Regul. 46 (2006) 314–323322Dewaste V, Moreau C, De Smedt F, Bex F, De Smedt H, Wuytack F, et al. The three isoenzymes of human
inositol-1,4,5-trisphosphate 3-kinase show speciﬁc intracellular localization but comparable Ca2+ responses
on transfection in COS-7 cells. Biochem J 2003;374:41–9.
Downes CP, Mussat MC, Michell RH. The inositol trisphosphate phosphomonoesterase of the human
erythrocyte membrane. Biochem J 1982;203:169–77.
Dubois E, Dewaste V, Erneux C, Messenguy F. Inositol polyphosphate kinase activity of Arg82/ArgRIII is not
required for the regulation of the arginine metabolism in yeast. FEBS Lett 2000;486:300–4.
Fischer M, Kaech S, Knutti D, Matus A. Rapid actin-based plasticity in dendritic spines. Neuron 1998;20:847–54.
Frederick JP, Mattiske D, Wofford JA, Megosh LC, Drake LY, Chiou ST, et al. An essential role for an inositol
polyphosphate multikinase, Ipk2, in mouse embryogenesis and second messenger production. Proc Natl Acad
Sci USA 2005;102:8454–9.
Gonzalez B, Schell MJ, Letcher AJ, Veprintsev DB, Irvine RF, Williams RL. Structure of a human inositol 1,4,5-
trisphosphate 3-kinase: substrate binding reveals why it is not a phosphoinositide 3-kinase. Mol Cell
2004;15:689–701.
Halpain S, Hipolito A, Saffer L. Regulation of F-actin stability in dendritic spines by glutamate receptors and
calcineurin. J Neurosci 1998;18:9835–44.
Irvine RF. How do inositol 1,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate regulate intracellular
Ca2+? Biochem Soc Trans 1989;17:6–9.
Irvine RF. Inositide evolution—towards turtle domination? J Physiol 2005;566:295–300.
Irvine RF, Schell MJ. Back in the water: the return of the inositol phosphates. Nat Rev Mol Cell Biol
2001;2:327–38.
Irvine RF, Letcher AJ, Heslop JP, Berridge MJ. The inositol tris/tetrakisphosphate pathway—demonstration of
Ins(1,4,5)P3 3-kinase activity in animal tissues. Nature 1986a;320:631–4.
Irvine RF, Letcher AJ, Lander DJ, Berridge MJ. Speciﬁcity of inositol phosphate-stimulated Ca2+ mobilization
from Swiss-mouse 3T3 cells. Biochem J 1986b;240:301–4.
Jun K, Choi G, Yang SG, Choi KY, Kim H, Chan GC, et al. Enhanced hippocampal CA1 LTP but normal
spatial learning in inositol 1,4,5-trisphosphate 3-kinase(A)-deﬁcient mice. Learn Mem 1998;5:317–30.
Lockyer PJ, Vanlingen S, Reynolds JS, McNulty TJ, Irvine RF, Parys JB, et al. Tissue-speciﬁc expression and
endogenous subcellular distribution of the inositol 1,3,4,5-tetrakisphosphate-binding proteins GAP1(IP4BP)
and GAP1(m). Biochem Biophys Res Comm 1999;255:421–6.
Loomis-Husselbee JW, Cullen PJ, Dreikausen UE, Irvine RF, Dawson AP. Synergistic effects of inositol 1,3,4,5-
tetrakisphosphate on inositol 2,4,5-triphosphate-stimulated Ca2+ release do not involve direct interaction of
inositol 1,3,4,5-tetrakisphosphate with inositol triphosphate-binding sites. Biochem J 1996;314:811–6.
Mailleux P, Takazawa K, Erneux C, Vanderhaeghen JJ. Inositol 1,4,5-trisphosphate 3-kinase distribution in the
rat brain. High levels in the hippocampal CA1 pyramidal and cerebellar Purkinje cells suggest its involvement
in some memory processes. Brain Res 1991;539:203–10.
Majewska A, Tashiro A, Yuste R. Regulation of spine calcium dynamics by rapid spine motility. J Neurosci
2000;20:8262–8.
Miller GJ, Hurley JH. Crystal structure of the catalytic core of inositol 1,4,5-trisphosphate 3-kinase. Mol Cell
2004;15:703–11.
Nalaskowski MM, Bertsch U, Fanick W, Stockebrand MC, Schmale H, Mayr GW. Rat inositol 1,4,5-
trisphosphate 3-kinase C is enzymatically specialized for basal cellular inositol trisphosphate phosphorylation
and shuttles actively between nucleus and cytoplasm. J Biol Chem 2003;278:19765–76.
Odom AR, Stahlberg A, Wente SR, York JD. A role for nuclear inositol 1,4,5-trisphosphate kinase in
transcriptional control. Science 2000;287:2026–9.
Patterson RL, van Rossum DB, Ford DL, Hurt KJ, Bae SS, Suh PG, et al. Phospholipase C-gamma is required
for agonist-induced Ca2+ entry. Cell 2002;111:529–41.
Pattni K, Banting G. Ins(1,4,5)P3 metabolism and the family of IP3-3 kinases. Cell Signal 2004;16:643–54.
Pattni K, Millard TH, Banting G. Calpain cleavage of the B isoform of Ins(1,4,5)P3 3-kinase separates the
catalytic domain from the membrane anchoring domain. Biochem J 2003;375:643–51.
Pouillon V, Hascakova-Bartova R, Pajak B, Adam E, Bex F, Dewaste V, et al. Inositol 1,3,4,5-tetrakisphosphate
is essential for T lymphocyte development. Nat Immunol 2003;4:1136–43.
Resnick AC, Snowman AM, Kang BN, Hurt KJ, Snyder SH, Saiardi A. Inositol polyphosphate multikinase is a
nuclear PI3-kinase with transcriptional regulatory activity. Proc Nat Acad Sci USA 2005;102:12783–8.
Saiardi A, Bhandari R, Resnick AC, Snowman AM, Snyder SH. Phosphorylation of proteins by inositol
pyrophosphates. Science 2004;306:2101–5.
ARTICLE IN PRESS
R.F. Irvine et al. / Advan. Enzyme Regul. 46 (2006) 314–323 323Schell MJ, Irvine RF. Calcium-triggered exit of F-actin and IP3 3-kinase A from dendritic spines is rapid and
reversible. Eur J Neurosci, 2006, in press.
Schell MJ, Erneux C, Irvine RF. Inositol 1,4,5-trisphosphate 3-kinase A associates with F-actin and dendritic
spines via its N terminus. J Biol Chem 2001;276:37537–46.
Shears SB. The pathway of myo-inositol 1,3,4-trisphosphate phosphorylation in liver. Identiﬁcation of myo-
inositol 1,3,4-trisphosphate 6-kinase, myo-inositol 1,3,4-trisphosphate 5-kinase, and myo-inositol 1,3,4,6-
tetrakisphosphate 5-kinase. J Biol Chem 1989;264:19879–86.
Shears SB. Assessing the functional omnipotence of inositol hexakisphophosphate. Cell Signal 2001;13:151–8.
Soriano S, Banting G. Possible roles of inositol 1,4,5-trisphosphate 3-kinase B in calcium homeostasis. FEBS Lett
1997;403:1–4.
Soriano S, Thomas S, High S, Grifﬁths G, D’Santos C, Cullen P, et al. Membrane association, localization and
topology of rat inositol 1,4,5-trisphosphate 3-kinase B: implications for membrane trafﬁc and Ca2+
homoeostasis. Biochem J 1997;324:579–89.
Speed CJ, Neylon CB, Little PJ, Mitchell CA. Underexpression of the 43 kDa inositol polyphosphate
5-phosphatase is associated with spontaneous calcium oscillations and enhanced calcium responses following
endothelin-1 stimulation. J Cell Sci 1999;112:669–79.
Streb H, Irvine RF, Berridge MJ, Schulz I. Release of Ca2+ from a nonmitochondrial intracellular store in
pancreatic acinar cells by inositol-1,4,5-trisphosphate. Nature 1983;306:67–9.
Verbsky J, Lavine K, Majerus PW. Disruption of the mouse inositol 1,3,4,5,6-pentakisphosphate 2-kinase gene,
associated lethality, and tissue distribution of 2-kinase expression. Proc Natl Acad Sci USA 2005;102:8448–53.
Wen BG, Pletcher MT, Warashina M, Choe SH, Ziaee N, Wiltshire T, et al. Inositol (1,4,5) trisphosphate 3 kinase
B controls positive selection of T cells and modulates Erk activity. Proc Natl Acad Sci USA 2004;101:5604–9.
York SJ, Armbruster BN, Greenwell P, Petes TD, York JD. Inositol diphosphate signaling regulates telomere
length. J Biol Chem 2005;280:4264–9.
Yu CHY, Lloyd-Burton SM, Irvine RF, Schell MJ. Regulation of the localisation and activity of inositol 1,4,5-
trisphosphate 3-kinase B in intact cells by proteolysis. Biochem J 2005;392:435–41.
